Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate

Roberto Cosentini, Francesco Blasi, Marco Trinchera, Domenico Sommariva, Angelo Fasoli

Research output: Contribution to journalArticle

Abstract

Bezafibrate was given for 15 days at a dose of 200 mg t.i.d. to 4 normolipidemic subjects, to 5 patients with putative heterozygous familial hypercholesterolemia, and to 6 patients with primary hypercholesterolemia of the non-familial type. At the end of the treatment, the rate of incorporation of labelled acetate into non-saponifiable lipids in freshly isolated blood mononuclear cells decreased in all subjects. On the average, acetate incorporation decreased by 31% in cells from normolipidemic subjects, 41% in cells from familial, and 45% in cells from non-familial hypercholesterolemia patients. Results of the present study suggest that the lowering effect of bezafibrate on serum cholesterol is mainly due to the inhibition of cholesterol synthesis through the suppression of HMG-CoA reductase as was demonstrated in rat hepatocytes and in cultured human blood mononuclear cells.

Original languageEnglish
Pages (from-to)253-255
Number of pages3
JournalAtherosclerosis
Volume79
Issue number2-3
DOIs
Publication statusPublished - 1989

Fingerprint

Bezafibrate
Blood Cells
Hyperlipoproteinemia Type II
Cholesterol
Acetates
Hydroxymethylglutaryl CoA Reductases
Hypercholesterolemia
Hepatocytes
Lipids
Serum
Therapeutics

Keywords

  • Bezafibrate
  • Blood mononuclear cells
  • Cholesterol synthesis
  • Serum cholesterol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate. / Cosentini, Roberto; Blasi, Francesco; Trinchera, Marco; Sommariva, Domenico; Fasoli, Angelo.

In: Atherosclerosis, Vol. 79, No. 2-3, 1989, p. 253-255.

Research output: Contribution to journalArticle

@article{842e65ab2cf84365a7c539274ea016fb,
title = "Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate",
abstract = "Bezafibrate was given for 15 days at a dose of 200 mg t.i.d. to 4 normolipidemic subjects, to 5 patients with putative heterozygous familial hypercholesterolemia, and to 6 patients with primary hypercholesterolemia of the non-familial type. At the end of the treatment, the rate of incorporation of labelled acetate into non-saponifiable lipids in freshly isolated blood mononuclear cells decreased in all subjects. On the average, acetate incorporation decreased by 31{\%} in cells from normolipidemic subjects, 41{\%} in cells from familial, and 45{\%} in cells from non-familial hypercholesterolemia patients. Results of the present study suggest that the lowering effect of bezafibrate on serum cholesterol is mainly due to the inhibition of cholesterol synthesis through the suppression of HMG-CoA reductase as was demonstrated in rat hepatocytes and in cultured human blood mononuclear cells.",
keywords = "Bezafibrate, Blood mononuclear cells, Cholesterol synthesis, Serum cholesterol",
author = "Roberto Cosentini and Francesco Blasi and Marco Trinchera and Domenico Sommariva and Angelo Fasoli",
year = "1989",
doi = "10.1016/0021-9150(89)90131-7",
language = "English",
volume = "79",
pages = "253--255",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate

AU - Cosentini, Roberto

AU - Blasi, Francesco

AU - Trinchera, Marco

AU - Sommariva, Domenico

AU - Fasoli, Angelo

PY - 1989

Y1 - 1989

N2 - Bezafibrate was given for 15 days at a dose of 200 mg t.i.d. to 4 normolipidemic subjects, to 5 patients with putative heterozygous familial hypercholesterolemia, and to 6 patients with primary hypercholesterolemia of the non-familial type. At the end of the treatment, the rate of incorporation of labelled acetate into non-saponifiable lipids in freshly isolated blood mononuclear cells decreased in all subjects. On the average, acetate incorporation decreased by 31% in cells from normolipidemic subjects, 41% in cells from familial, and 45% in cells from non-familial hypercholesterolemia patients. Results of the present study suggest that the lowering effect of bezafibrate on serum cholesterol is mainly due to the inhibition of cholesterol synthesis through the suppression of HMG-CoA reductase as was demonstrated in rat hepatocytes and in cultured human blood mononuclear cells.

AB - Bezafibrate was given for 15 days at a dose of 200 mg t.i.d. to 4 normolipidemic subjects, to 5 patients with putative heterozygous familial hypercholesterolemia, and to 6 patients with primary hypercholesterolemia of the non-familial type. At the end of the treatment, the rate of incorporation of labelled acetate into non-saponifiable lipids in freshly isolated blood mononuclear cells decreased in all subjects. On the average, acetate incorporation decreased by 31% in cells from normolipidemic subjects, 41% in cells from familial, and 45% in cells from non-familial hypercholesterolemia patients. Results of the present study suggest that the lowering effect of bezafibrate on serum cholesterol is mainly due to the inhibition of cholesterol synthesis through the suppression of HMG-CoA reductase as was demonstrated in rat hepatocytes and in cultured human blood mononuclear cells.

KW - Bezafibrate

KW - Blood mononuclear cells

KW - Cholesterol synthesis

KW - Serum cholesterol

UR - http://www.scopus.com/inward/record.url?scp=0024449692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024449692&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(89)90131-7

DO - 10.1016/0021-9150(89)90131-7

M3 - Article

C2 - 2597233

AN - SCOPUS:0024449692

VL - 79

SP - 253

EP - 255

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2-3

ER -